Samsung Biologics : Material Business Matters Related to Investment Decisions

Material Business Matters Related to Investment Decisions

1. Title	Signing of Tech Transfer Agreement(TTA) for contract manufacturing of biologics
2. Details	1) Counterparty to contract : European pharmaceutical company 2) Contract amount : KRW 154,093,728,300 3) Date of TTA signing : 2022.04.25 4) Contract period : 2022.04.25 ~ 2022.08.31
3. Date of board resolution (decision date) or confirmation date	2022-04-25
- Attendance of outside directors	Present(No.)	-
Absent(No.)	-
- Attendance of auditors (members of Audit Committee who are not outside directors)	-
4. Other matters to be factored into investment decisions
- The above contract amount is the amount obtained by applying the first published basic rate of trading (USD/KRW 1,241.70) on April 25, 2022 to the finalized contract amount of USD 124,099,000. The above contract amount is equivalent to 9.38% of the company's sales (KRW 1,568,006,928,039) of the latest fiscal year (FY 2021). - The above contract amount is binding on the two companies under the contract, and when the main contract is concluded in the future, the confirmed details will be disclosed. - Counterparty to contract will be disclosed on August 31, 2022 due to business confidentiality.
※ Related disclosure	-

【Information Related to Disclosure Withheld】

1. Disclosure matters to be withheld	Counterparty to contract
2. Reasons for withholding disclosure	Business Confidentiality
3. Withholding period	2022-08-31